Literature DB >> 9535046

Pseudomembraneous clostridium after autologous bone marrow transplantation.

P Kavan1, M Sochor, O Nyc, O Lochmann, J Koutecky, P J Skala, L K McClain.   

Abstract

Clostridium difficile (C. difficile) pseudomembraneous colitis was diagnosed in a 13-year-old boy with Hodgkin's disease 3 months after autologous bone marrow transplantation. Hematopoiesis was fully reconstituted at the time. C. difficile infection occurred after gall bladder empyema had been treated conservatively with i.v. antibiotics and prophylactic 4-week administration of oral amoxicillin. C. difficile colitis was diagnosed early and intensive supportive therapy combined with administration of i.v. and subsequently oral vancomycin therapy failed. It is a phenomenon rarely seen and successful eradication of the clostridium infection was only achieved by a combination of higher dose vancomycin with metronidazole. During the post-colitis recovery the patient experienced a relapse of Hodgkin's disease and died following further surgical intervention 137 days post-transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535046     DOI: 10.1038/sj.bmt.1701117

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation.

Authors:  Teena Chopra; Pranatharthi Chandrasekar; Hossein Salimnia; Lance K Heilbrun; Daryn Smith; George J Alangaden
Journal:  Clin Transplant       Date:  2010-10-25       Impact factor: 2.863

2.  Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes.

Authors:  Erik R Dubberke; Kimberlay A Reske; Anand Srivastava; Justin Sadhu; Robert Gatti; Rebecca M Young; Lauren C Rakes; Brian Dieckgraefe; John DiPersio; Victoria J Fraser
Journal:  Clin Transplant       Date:  2009-07-13       Impact factor: 2.863

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.